Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Flexion Therapeutics

Nasdaq:FLXN
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FLXN
Nasdaq
$317M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Flexion Therapeutics has significant price volatility in the past 3 months.
FLXN Share Price and Events
7 Day Returns
36.8%
NasdaqGM:FLXN
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-34.2%
NasdaqGM:FLXN
1.6%
US Biotechs
-9.1%
US Market
FLXN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Flexion Therapeutics (FLXN) 36.8% -47.1% -60.8% -34.2% -69.5% -64.4%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • FLXN underperformed the Biotechs industry which returned 1.6% over the past year.
  • FLXN underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
FLXN
Industry
5yr Volatility vs Market
Related Companies

FLXN Value

 Is Flexion Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Flexion Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Flexion Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Flexion Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $8.21.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Flexion Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Flexion Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:FLXN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.93
NasdaqGM:FLXN Share Price ** NasdaqGM (2020-03-27) in USD $8.21
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Flexion Therapeutics.

NasdaqGM:FLXN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:FLXN Share Price ÷ EPS (both in USD)

= 8.21 ÷ -3.93

-2.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Flexion Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Flexion Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Flexion Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:FLXN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
62.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Flexion Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Flexion Therapeutics's assets?
Raw Data
NasdaqGM:FLXN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.52
NasdaqGM:FLXN Share Price * NasdaqGM (2020-03-27) in USD $8.21
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:FLXN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:FLXN Share Price ÷ Book Value per Share (both in USD)

= 8.21 ÷ -0.52

-15.66x

* Primary Listing of Flexion Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Flexion Therapeutics has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at Flexion Therapeutics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Flexion Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Flexion Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Flexion Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FLXN Future Performance

 How is Flexion Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Flexion Therapeutics expected to grow at an attractive rate?
  • Flexion Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Flexion Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Flexion Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:FLXN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:FLXN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 62.3%
NasdaqGM:FLXN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 31.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:FLXN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:FLXN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 464 185 132 4
2023-12-31 382 108 87 4
2022-12-31 300 18 26 6
2021-12-31 202 -48 -57 8
2020-12-31 118 -103 -118 9
2020-03-28
NasdaqGM:FLXN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 73 -149 -150
2019-09-30 59 -152 -157
2019-06-30 44 -157 -162
2019-03-31 31 -153 -170
2018-12-31 23 -160 -170
2018-09-30 13 -160 -180
2018-06-30 6 -148 -170
2018-03-31 3 -131 -155
2017-12-31 0 -108 -137
2017-09-30 -87 -110
2017-06-30 -79 -94
2017-03-31 -70 -79

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Flexion Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Flexion Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:FLXN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Flexion Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:FLXN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 3.13 4.52 1.97 4.00
2023-12-31 1.77 2.48 0.95 4.00
2022-12-31 0.52 1.00 0.11 5.00
2021-12-31 -1.39 -0.98 -1.93 7.00
2020-12-31 -3.08 -2.96 -3.19 8.00
2020-03-28
NasdaqGM:FLXN Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.93
2019-09-30 -4.13
2019-06-30 -4.28
2019-03-31 -4.48
2018-12-31 -4.49
2018-09-30 -4.80
2018-06-30 -4.73
2018-03-31 -4.50
2017-12-31 -4.16
2017-09-30 -3.53
2017-06-30 -3.11
2017-03-31 -2.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Flexion Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Flexion Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Flexion Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FLXN Past Performance

  How has Flexion Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Flexion Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Flexion Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Flexion Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Flexion Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Flexion Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Flexion Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:FLXN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 72.96 -149.77 129.71 69.56
2019-09-30 58.85 -156.83 128.18 67.34
2019-06-30 44.05 -162.24 128.79 59.98
2019-03-31 30.89 -169.63 126.68 56.95
2018-12-31 22.52 -169.66 121.31 53.08
2018-09-30 13.34 -179.61 123.01 54.08
2018-06-30 6.35 -170.16 108.58 53.35
2018-03-31 2.55 -155.17 92.67 52.03
2017-12-31 0.36 -137.48 78.80 51.23
2017-09-30 -110.07 56.70 46.75
2017-06-30 -93.66 46.72 42.95
2017-03-31 -78.96 36.80 40.09
2016-12-31 -71.89 28.47 41.31
2016-09-30 -62.35 22.81 36.72
2016-06-30 -55.71 17.61 35.50
2016-03-31 -53.96 15.30 36.24
2015-12-31 -46.32 13.37 32.69
2015-09-30 -40.55 11.10 29.22
2015-06-30 -36.45 10.21 26.05
2015-03-31 -29.95 9.54 20.03
2014-12-31 -27.31 9.06 17.92
2014-09-30 -23.20 8.16 14.66
2014-06-30 -21.26 8.28 12.57
2014-03-31 -19.93 7.47 12.03
2013-12-31 -18.19 6.70 11.06
2013-09-30 -18.59 6.47 11.83
2013-06-30 -18.04 5.03 12.84
2013-03-31 -16.61 4.54 12.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Flexion Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Flexion Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Flexion Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Flexion Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Flexion Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FLXN Health

 How is Flexion Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Flexion Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Flexion Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Flexion Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Flexion Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Flexion Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Flexion Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:FLXN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -20.11 193.59 136.72
2019-09-30 7.17 191.27 175.82
2019-06-30 41.47 158.00 171.57
2019-03-31 72.58 158.22 218.14
2018-12-31 110.08 158.49 258.85
2018-09-30 146.11 158.80 302.93
2018-06-30 185.51 159.16 340.46
2018-03-31 222.61 159.56 371.71
2017-12-31 260.27 160.01 392.44
2017-09-30 173.65 160.50 335.16
2017-06-30 203.38 161.04 359.86
2017-03-31 166.10 29.88 185.82
2016-12-31 187.03 30.53 205.60
2016-09-30 138.03 30.30 159.50
2016-06-30 154.03 15.15 163.26
2016-03-31 88.90 15.07 98.36
2015-12-31 103.99 15.00 111.25
2015-09-30 115.71 14.94 132.17
2015-06-30 125.66 0.00 127.37
2015-03-31 136.83 0.00 132.35
2014-12-31 144.94 3.56 151.62
2014-09-30 59.79 4.08 66.59
2014-06-30 66.13 4.57 71.99
2014-03-31 71.38 5.06 78.51
2013-12-31 10.10 5.05 16.44
2013-09-30 13.56 5.04 21.00
2013-06-30 17.98 5.02 24.91
2013-03-31 27.28 0.00 29.38
  • Flexion Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Flexion Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Flexion Therapeutics has less than a year of cash runway based on current free cash flow.
  • Flexion Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 34.9% each year.
X
Financial health checks
We assess Flexion Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Flexion Therapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FLXN Dividends

 What is Flexion Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Flexion Therapeutics dividends.
If you bought $2,000 of Flexion Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Flexion Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Flexion Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:FLXN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:FLXN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Flexion Therapeutics has not reported any payouts.
  • Unable to verify if Flexion Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Flexion Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Flexion Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Flexion Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Flexion Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Flexion Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FLXN Management

 What is the CEO of Flexion Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Clayman
COMPENSATION $3,221,631
AGE 67
TENURE AS CEO 13.2 years
CEO Bio

Dr. Michael D. Clayman, also known as Mike, M.D., Co-Founded Flexion Therapeutics, Inc. (formerly, Flexion Development Partners, Inc) in 2007 and has been its Chief Executive Officer and President since 2007 and was its Principal Financial Officer and Principal Accounting Officer until May 7, 2018. Dr. Clayman has over 20 years of experience in pharmaceutical development. He served as Vice President at Lilly Research Laboratories at Eli Lilly and Company and its General Manager of Chorus, Lilly's development accelerator. During a long career at Lilly, Dr. Clayman led major components of Lilly Research Laboratories including Global Regulatory Affairs (where he managed seven global submissions), Cardiovascular Discovery Research and Clinical Investigation, Product Development and Technology at Advanced Cardiovascular Systems (a subsidiary of Eli Lilly), the Internal Medicine Division and the Lilly Clinic (Eli Lilly's dedicated Phase I unit). He has been a Director at Flexion Therapeutics, Inc. since 2007. He was a Director of Akebia Therapeutics, Inc. since July 28, 2014 until December 12, 2018. He served as the Chair of Lilly's Bioethics Committee. He serves as an Assistant Professor in the School of Medicine at the University of Pennsylvania and is a recipient of the Physician Scientist Award from the National Institutes of Health. Dr. Clayman received a BA, cum laude, from Yale University and an MD from the University of California-San Diego School of Medicine. Following internship and residency in internal medicine at the UC San Francisco Moffitt Hospitals, he completed clinical and research fellowships in nephrology at the University of Pennsylvania.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Flexion Therapeutics management team in years:

3.5
Average Tenure
53
Average Age
  • The tenure for the Flexion Therapeutics management team is about average.
Management Team

Mike Clayman

TITLE
Co-Founder
COMPENSATION
$3M
AGE
67
TENURE
13.2 yrs

David Arkowitz

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
58
TENURE
1.8 yrs

Mark Levine

TITLE
General Counsel & Secretary
COMPENSATION
$1M
AGE
46
TENURE
2.8 yrs

Scott Kelley

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
60
TENURE
2.3 yrs

Scott Young

TITLE
VP of Corporate Communications & Investor Relations

Carolyn Scimemi

TITLE
VP, Legal Affairs & Chief Compliance Officer
TENURE
3.5 yrs

John Magee

TITLE
Vice President of Sales
TENURE
3.5 yrs

Christina Willwerth

TITLE
Chief Strategy Officer
AGE
48
TENURE
3.5 yrs

Dan Leblanc

TITLE
Senior Vice President of CMC Operations
TENURE
3.5 yrs

Kerry Wentworth

TITLE
Chief Regulatory Officer
AGE
46
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the Flexion Therapeutics board of directors in years:

7.3
Average Tenure
58
Average Age
  • The tenure for the Flexion Therapeutics board of directors is about average.
Board of Directors

Patrick Mahaffy

TITLE
Independent Chairman
COMPENSATION
$406K
AGE
56
TENURE
11.2 yrs

Mike Clayman

TITLE
Co-Founder
COMPENSATION
$3M
AGE
67
TENURE
13.2 yrs

Sam Colella

TITLE
Independent Director
COMPENSATION
$288K
AGE
79
TENURE
12.2 yrs

Alan Milinazzo

TITLE
Independent Director
COMPENSATION
$280K
AGE
59
TENURE
9.2 yrs

Sandy Mahatme

TITLE
Independent Director
COMPENSATION
$291K
AGE
54
TENURE
5.7 yrs

Heath Lukatch

TITLE
Independent Director
AGE
52
TENURE
7.3 yrs

C. Merrifield

TITLE
Independent Director
COMPENSATION
$281K
AGE
68
TENURE
5.8 yrs

Scott Canute

TITLE
Independent Director
COMPENSATION
$276K
AGE
58
TENURE
5 yrs

Mark Stejbach

TITLE
Independent Director
COMPENSATION
$281K
AGE
56
TENURE
3.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
09. Aug 19 Buy Samuel Colella Individual 08. Aug 19 08. Aug 19 2,000 $10.74 $21,480
08. Aug 19 Buy Michael Clayman Individual 08. Aug 19 08. Aug 19 2,317 $10.85 $25,136
03. Jun 19 Buy David Arkowitz Individual 31. May 19 31. May 19 2,500 $11.05 $27,627
24. May 19 Buy C. Merrifield Individual 23. May 19 23. May 19 8,000 $12.64 $101,120
15. May 19 Buy David Arkowitz Individual 13. May 19 13. May 19 4,000 $11.99 $47,960
13. May 19 Buy Michael Clayman Individual 10. May 19 10. May 19 4,012 $12.48 $50,067
X
Management checks
We assess Flexion Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Flexion Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FLXN News

Simply Wall St News

Does Flexion Therapeutics, Inc. (NASDAQ:FLXN) Have A Volatile Share Price?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … If this beta value holds true in the future, Flexion Therapeutics shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since Flexion Therapeutics tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.

Simply Wall St -

Loss-Making Flexion Therapeutics, Inc. (NASDAQ:FLXN) Expected To Breakeven

Flexion Therapeutics, Inc.'s (NASDAQ:FLXN): Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. … Check out our latest analysis for Flexion Therapeutics FLXN is bordering on breakeven, according to the 9 Biotechs analysts. … Next Steps: There are too many aspects of FLXN to cover in one brief article, but the key fundamentals for the company can all be found in one place – FLXN’s company page on Simply Wall St.

Simply Wall St -

Flexion Therapeutics (NASDAQ:FLXN) Seems To Be Really Weighed Down By Its Debt

NasdaqGM:FLXN Historical Debt, July 11th 2019 How Healthy Is Flexion Therapeutics's Balance Sheet? … The latest balance sheet data shows that Flexion Therapeutics had liabilities of US$39.2m due within a year, and liabilities of US$152.8m falling due after that. … This surplus suggests that Flexion Therapeutics has a conservative balance sheet, and could probably eliminate its debt without much difficulty.

Simply Wall St -

Introducing Flexion Therapeutics (NASDAQ:FLXN), The Stock That Slid 59% In The Last Year

Check out our latest analysis for Flexion Therapeutics Flexion Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last year Flexion Therapeutics saw its revenue grow by 1112%. … A Different Perspective Flexion Therapeutics shareholders are down 59% for the year, but the market itself is up 0.1%.

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For Flexion Therapeutics, Inc. (NASDAQ:FLXN)?

(NASDAQ:FLXN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … What this means for you: Since Flexion Therapeutics has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Did Flexion Therapeutics, Inc. (NASDAQ:FLXN) Insiders Buy Up More Shares?

So before you buy or sell Flexion Therapeutics, Inc. … The Last 12 Months Of Insider Transactions At Flexion Therapeutics. … In the last twelve months there was more buying than selling by Flexion Therapeutics insiders

Simply Wall St -

Loss-Making Flexion Therapeutics, Inc. (NASDAQ:FLXN) Expected To Breakeven

Flexion Therapeutics, Inc.'s (NASDAQ:FLXN):. … Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. … The company’s loss has recently broadened since it announced a -US$137.5m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$179.6m, moving it further away from breakeven?

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For Flexion Therapeutics Inc (NASDAQ:FLXN)?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Is There An Opportunity With Flexion Therapeutics Inc's (NASDAQ:FLXN) 49.77% Undervaluation?

by taking the foreast future cash flows of the company and discounting them back to today's value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Market Sentiment Around Loss-Making Flexion Therapeutics Inc (NASDAQ:FLXN)

Flexion Therapeutics Inc's (NASDAQ:FLXN):. … Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. … In this article, I will touch on the expectations for FLXN’s growth and when analysts expect the company to become profitable

Simply Wall St -

FLXN Company Info

Description

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Details
Name: Flexion Therapeutics, Inc.
FLXN
Exchange: NasdaqGM
Founded: 2007
$316,509,506
38,551,706
Website: http://www.flexiontherapeutics.com
Address: Flexion Therapeutics, Inc.
10 Mall Road,
Suite 301,
Burlington,
Massachusetts, 01803,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM FLXN Common Stock Nasdaq Global Market US USD 12. Feb 2014
BRSE F02 Common Stock Berne Stock Exchange CH CHF 12. Feb 2014
Number of employees
Current staff
Staff numbers
288
Flexion Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:26
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.